GeoVax’s Gedeptin Enhances PD-1 Response in Triple-Negative Breast Cancer, Plans Head and Neck Cancer Trial
GOVX•GeoVax highlighted preclinical data showing its Gedeptin platform enhanced PD-1/PD-L1 checkpoint inhibitor responses and generated anti-tumor immunity in checkpoint-resistant triple-negative breast cancer models. The company plans a neoadjuvant study injecting Gedeptin with PD-1 blockade in recurrent head and neck squamous cell carcinoma to improve tumor microenvironment activation before curative-intent surgery.
1. Preclinical Evidence of Immune Activation
GeoVax’s published findings demonstrate that its gene-directed enzyme-prodrug therapy platform, Gedeptin, enhances PD-1/PD-L1 checkpoint inhibitor responses in preclinical models of checkpoint-resistant triple-negative breast cancer. The study reported activation of anti-tumor immunity, strong bystander killing effects and systemic immune engagement in both treated tumors and distant untreated sites.
2. Strategic Implications for Immunotherapy
GeoVax positions Gedeptin as a solution to the cold tumor barrier by remodeling the tumor microenvironment and priming immune recognition. The platform is designed to complement, not compete with, existing checkpoint therapies and represents a potential commercial opportunity through combination regimens and partnership avenues.
3. Planned Neoadjuvant Head and Neck Cancer Study
The company will initiate a neoadjuvant trial in recurrent head and neck squamous cell carcinoma, administering intratumoral Gedeptin alongside PD-1 immunotherapy and standard of care prior to curative-intent surgery. This setting leverages tumor accessibility and intact antigen sources to maximize immune priming and potentially improve surgical and long-term outcomes.
